The Chinese drug administration denied the application of Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Zhijun (Shenzhen) Pharmaceutical, to market fosfomycin tromethamine granules, according to a Shanghai Stock Exchange disclosure on Friday.
The application did not meet relevant requirements for drug registration, the pharmaceutical company said.
The drug was developed to treat infections caused by sensitive Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter, Enterobacter, and Proteus mirabilis, such as acute simple urinary tract infection.
The company, which spent 11.5 million yuan into the drug's research and development, said it will re-initiate the research, application and registration work for the drug.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。